

STERLING BIOTECH LIMITED

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE SECOND QUARTER ENDED 30 JUNE 2011

(Rs. in Lacs)

Sr. No.	Particulars	Quarter ended 30/06/2011	Corresponding Quarter ended 30/06/2010	SIX Months Ended 30/06/2011	Corresponding SIX Months Ended 30/06/2010	For the Year ended 31/12/2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income					
	a) Net Sales/Income from Operations	44,605.17	39,598.22	88,433.32	77,876.47	161,657.85
	b) Other Operating Income	193.71	196.39	520.06	408.73	1,063.76
	c) Total	44,798.88	39,794.61	88,953.38	78,285.20	162,721.61
2	Expenditure					
	a) (Increase)/decrease in stock in trade and work in progress	(413.90)	(7,351.00)	(5,101.92)	(8,418.84)	(9,332.32)
	b) Consumption of raw materials	22,767.86	27,849.44	42,639.34	48,452.45	89,387.90
	c) Employees Cost	1,217.04	1,187.39	2,395.96	2,209.86	4,371.50
	d) Depreciation	6,873.28	4,041.96	12,787.82	7,265.81	19,762.17
	e) Other expenditure	2,218.52	1,823.78	9,867.31	3,668.97	7,522.53
	f) Total	32,662.80	27,551.57	62,588.51	53,178.25	111,711.78
3	Profit / (Loss) from Operations before Other Income and Interest (1-2)	12,136.08	12,243.04	26,364.87	25,106.95	51,009.83
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) before Interest (3+4)	12,136.08	12,243.04	26,364.87	25,106.95	51,009.83
6	Interest	6,273.94	5,218.43	12,591.58	10,745.97	23,047.05
7	Profit / (Loss) from Ordinary Activities before tax (5-6)	5,862.14	7,024.61	13,773.29	14,360.98	27,962.78
8	Tax expense					
	a) Current	935.67	1,360.00	2,495.67	2,570.00	4,020.00
	b) Deferred	608.18	950.00	1,708.18	2,150.00	3,100.00
	c) Fringe Benefit	0.00	0.00	0.00	0.00	0.00
	d) Total	1,543.85	2,310.00	4,203.85	4,720.00	7,120.00
9	Net Profit / (Loss) from Ordinary Activities after tax (7-8)	4,318.29	4,714.61	9,569.44	9,640.98	20,842.78
10	Extraordinary Items	(1,183.81)	(244.18)	(1,305.68)	(466.36)	(6,310.48)
11	Net Profit / (Loss) for the period (9-10)	3,134.48	4,470.43	8,263.76	9,174.62	14,532.30
12	Prior year adjustment	0.00	0.00	0.00	0.00	88.39
13	Profit available for appropriation	3,134.48	4,470.43	8,263.76	9,174.62	14,620.69
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,678.74	2,501.97	2,678.74	2,501.97	2,678.74
15	Reserves excluding Revaluation Reserves as per balance sheet.					244,415.28
16	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.					
	Basic	1.61	1.88	3.57	3.85	8.16
	Diluted	1.43	1.56	3.16	3.19	7.19
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.					
	Basic	1.17	1.79	3.08	3.67	5.69
	Diluted	1.04	1.48	2.73	3.03	5.01
17	Public Shareholding					
	- Number of shares	133,666,531	133,666,531	133,666,531	133,666,531	133,666,531
	- Percentage of shareholding	49.90%	53.42%	49.90%	53.42%	49.90%

STERLING BIOTECH LIMITED

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE SECOND QUARTER ENDED 30 JUNE 2011

(Rs. in Lacs)

Sr. No.	Particulars	Quarter ended 30/06/2011	Corresponding Quarter ended 30/06/2010	SIX Months Ended 30/06/2011	Corresponding SIX Months Ended 30/06/2010	For the Year ended 31/12/2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
18	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	Number of shares	27,909,340	30,527,000	27,909,340	30,527,000	18,228,340
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	31.35%	34.29%	31.35%	34.29%	20.47%
	Percentage of shares (as a % of the total share capital of the Company)	10.42%	12.20%	10.42%	12.20%	6.80%
	b) Non-encumbered					
	Number of shares	61,125,354	58,507,694	61,125,354	58,507,694	70,806,354
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	68.65%	65.71%	68.65%	65.71%	79.53%
	Percentage of shares (as a % of the total share capital of the Company)	22.82%	23.38%	22.82%	23.38%	26.43%

Notes:

1 Statement of Assets and Liabilities

(Rs. in Lacs)

Sr. No.	Particulars	SIX Months Ended 30/06/2011	Corresponding SIX Months Ended 30/06/2010	TWELVE Months Ended 31/12/2010
		Unaudited	Unaudited	Audited
1	SHAREHOLDERS' FUNDS			
	a) Capital	2,678.74	2,501.97	2,678.74
	b) Reserves and Surplus	252,679.04	213,705.16	244,415.28
2	LOAN FUNDS	364,360.94	369,374.89	374,383.99
3	Deferred Tax Liability	32,890.18	30,232.00	31,182.00
	TOTAL	652,608.90	615,814.02	652,660.01
4	FIXED ASSETS	404,820.11	405,665.73	410,766.02
5	INVESTMENTS	36,284.60	27,593.94	36,392.91
6	CURRENT ASSETS, LOANS AND ADVANCES			
	a) Inventories	78,896.05	67,446.25	68,551.04
	b) Sundry Debtors	69,723.47	58,864.75	67,641.02
	c) Cash and Bank Balances	7,656.18	9,316.42	15,837.21
	d) Loans and Advances	65,240.99	55,289.36	64,953.65
	Less: Current Liabilities and Provisions			
	a) Liabilities	6,315.46	6,715.70	6,504.21
	b) Provisions	4,062.66	2,570.00	5,586.99
7	MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)	365.62	923.26	609.36
	TOTAL	652,608.90	615,814.02	652,660.01

2 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.

3 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 12 August 2011.

4 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30 June 2011.

5 The number of investor complaints for the quarter ended on 30 June 2011 were :
Opening - NIL, Received - 11, Disposed off - 11, and Balance - NIL.

6 Previous period figures have been regrouped/reclassified, wherever necessary.

For and on Behalf of
STERLING BIOTECH LIMITED

Place : Mumbai
Date : 12 August 2011.

Chetan J. Sandesara
Joint Managing Director